Stiles Financial Services Inc Has $2.77 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stiles Financial Services Inc lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.5% during the 4th quarter, HoldingsChannel reports. The fund owned 3,896 shares of the biopharmaceutical company’s stock after purchasing an additional 464 shares during the period. Regeneron Pharmaceuticals comprises approximately 1.0% of Stiles Financial Services Inc’s portfolio, making the stock its 29th largest holding. Stiles Financial Services Inc’s holdings in Regeneron Pharmaceuticals were worth $2,774,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Kestra Private Wealth Services LLC boosted its stake in shares of Regeneron Pharmaceuticals by 12.9% during the fourth quarter. Kestra Private Wealth Services LLC now owns 1,926 shares of the biopharmaceutical company’s stock valued at $1,372,000 after purchasing an additional 220 shares in the last quarter. Howland Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 1,127.1% in the 4th quarter. Howland Capital Management LLC now owns 15,437 shares of the biopharmaceutical company’s stock valued at $10,996,000 after buying an additional 14,179 shares during the last quarter. Entropy Technologies LP boosted its position in Regeneron Pharmaceuticals by 1,225.0% during the 4th quarter. Entropy Technologies LP now owns 5,300 shares of the biopharmaceutical company’s stock worth $3,775,000 after buying an additional 4,900 shares during the period. Empowered Funds LLC grew its holdings in Regeneron Pharmaceuticals by 687.5% during the 4th quarter. Empowered Funds LLC now owns 13,010 shares of the biopharmaceutical company’s stock worth $9,267,000 after acquiring an additional 11,358 shares during the last quarter. Finally, Forbes J M & Co. LLP increased its position in Regeneron Pharmaceuticals by 150.7% in the 4th quarter. Forbes J M & Co. LLP now owns 519 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 312 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $710.00 on Monday. The firm has a market capitalization of $78.02 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock has a 50 day moving average price of $715.81 and a two-hundred day moving average price of $910.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on REGN. Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup cut their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Finally, Royal Bank of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.